Experimental vaccine takes on tough pancreatic cancer
NCT ID NCT07231094
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial will test a new tumor vaccine (SapDM275) combined with standard chemotherapy in 13 people with metastatic pancreatic cancer who have not had prior treatment. The vaccine aims to help the immune system attack cancer cells. The main goal is to check safety, but researchers will also look for signs of tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SapDM275 tumor vaccine (targets MICA/B proteins) plus AG chemotherapy (nab-paclitaxel and gemcitabine)
What this could lead to
If it works, this could point toward a new treatment option for metastatic pancreatic cancer, potentially improving tumor shrinkage or delaying progression.
What could go wrong
This is a very early, small trial (13 people) focused on safety, not proof of effectiveness. The vaccine may not shrink tumors or could cause side effects. Many early-stage cancer vaccines fail in later testing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Third Xiangya Hospital of Central South University
Hunan, Changsha, 410000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••